Resuscitation Therapeutics, Inc. (RTx), an RFU early-stage company, | facebook.com/rfums/
Resuscitation Therapeutics, Inc. (RTx), an RFU early-stage company, | facebook.com/rfums/
Resuscitation Therapeutics, Inc. (RTx), an RFU early-stage company,
Resuscitation Therapeutics, Inc. (RTx), an RFU early-stage company, is preparing an Investigational New Drug application for the U.S. Food and Drug Administration for a therapy that could increase the current 10% survival rate for out-of-hospital cardiac arrest.
RTx was founded in 2017 by our very own Dr. Raúl J. Gazmuri, professor of medicine and professor of physiology and biophysics at Chicago Medical School — we applaud your dedication to advancing and proposing novel treatment for sudden cardiac arrest.
“It’s our great hope that this potential therapeutic solution for sudden cardiac arrest will save many lives in the U.S. and around the world," said Dr. Ronald Kaplan, executive vice president for research.
Original source can be found here
Alerts Sign-up